Hirsch S. Ruchlin|James M. Pellissier
An economic overview of prostate carcinoma
Cornell University|MSD (United States)
united states 2000 180400 new cases prostate carcinoma expected occur 31900 men expected die illness addition prostate carcinoma cause half million disabilityadjusted lifeyears study summarizes current body published literature economics prostate carcinomathe authors used medlinebased literature review relevant articles 1990 presentthe authors search returned 216 articles 56 met criteria interest prostate carcinoma costly treat currently averaging 20000 per case cost care directly related stage disease comorbidity substantial geographic variation exists even within small locales regard care patterns cost inhospital mortality length stay cost inversely related case volume care rendered health maintenance organizations generally less technologically intensive feeforservice sector 18 cost studies examined 13 costminimization analyses five assessed costeffectiveness cost perspective laparoscopic pelvic node dissection favored open pelvic procedure 3d conformal radiation therapy favored 2d radiation therapy favored radical prostatectomy costeffectiveness analyses favored use metastron mitroxantone plus prednisone prednisone alone flutamine either medical surgical castration orchiectomy androgen suppression therapythe literature economics prostate carcinoma relatively meager cost studies done small samples short followup periods used charges rather cost data include adequate representation stages disease additional research needed